Latest On ERYTECH Pharma S.A (ERYP):
About ERYTECH Pharma S.A (ERYP):
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine-dependent cancers. It has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was incorporated in 2004 and is headquartered in Lyon, France.
General
- Name ERYTECH Pharma S.A
- Symbol ERYP
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 206
- Fiscal Year EndDecember
- IPO Date2016-07-05
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://www.erytech.com
Valuation
- Price/Book (Most Recent Quarter) 4.95
Financials
- Most Recent Quarter 2020-12-31
- Return on Assets -43%
- Return on Equity -131%
- Earnings Per Share -$2.79
- Revenue Per Share $0
- Gross Profit 3.72 million
- Quarterly Earnings Growth -40.9%
Highlights
- Market Capitalization 149.69 million
- Analyst Target Price $17.83
- Book Value Per Share $10.64
Share Statistics
- Shares Outstanding 21.14 million
- Shares Float 13.19 million
- % Held by Insiders <1%
- % Held by Institutions 7.05%
- Shares Short 4359
- Shares Short Prior Month 45877
- Short Ratio 0.07
Technicals
- Beta 2.01
- 52 Week High $13
- 52 Week Low $3.5
- 50 Day Moving Average 9.1
- 200 Day Moving Average 8.24
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
ERYTECH Pharma S.A (ERYP) Dividend Calendar:
Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
---|
ERYTECH Pharma S.A (ERYP) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
---|---|---|---|---|---|
2019-12-31 | 2020-03-16 | $N/A | -$1.18 | -$0.92 | -27.45% |
2018-12-31 | 2019-03-11 | $2.09 million | -$0.45 | -$0.60 | 25% |
ERYTECH Pharma S.A (ERYP) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
Date |
---|
Research Development |
Income Before Tax |
Selling General Administrative |
Gross Profit |
Ebit |
Operating Income |
Income Tax Expense |
Total Revenue |
Cost of Revenue |
Total Other Income Expense Net |
Net Income From Continuing Operations |
Net Income Applicable to Common Shares |
Cash Flow:
Date |
---|
Investments |
Change to Liabilities |
Total Cash Flow from Investing Activities |
Net Borrowings |
Total Cash Flow from Financial Activities |
Change to Operating Activities |
Change in Cash |
Total Cash from Operating Activities |
Depreciation |
Other Cash Flow from Investing Activities |
Change to Inventory |
Change to Account Receivables |
Other Cash Flow from Financing Activities |
Change to Net Income |
Capital Expenditures |
Balance Sheet:
Date |
---|
Total Liabailities |
Total Stockholder Equity |
Other Current Liabilities |
Total Assets |
Common Stock |
Other Current Assets |
Retained Earnings |
Other Liabilities |
Other Assets |
Cash |
Total Current Liabilities |
Other Stockholder Equity |
Property, Plant & Equipment |
Total Current Assets |
Long Term Investments |
Net Tangible Assets |
Short Term Investments |
Long Term Debt |
Inventory |
Accounts Payable |
ERYTECH Pharma S.A (ERYP) Chart:
ERYTECH Pharma S.A (ERYP) News:
Below you will find a list of latest news for ERYTECH Pharma S.A (ERYP) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
ERYTECH Pharma S.A (ERYP) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
---|
Latest ERYP Trades:
Date | Shares | Price |
---|---|---|
Jun 13, 2022 1:49 PM EST | 100 | $1.07 |
ERYTECH Pharma S.A (ERYP) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
Date | Form Type | Form Name | Link |
---|---|---|---|
2020-06-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520181121/0001193125-20-181121-index.htm |
2019-07-18 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1624422/000000000019011290/0000000000-19-011290-index.htm |
2018-07-02 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1624422/000092189518002043/0000921895-18-002043-index.htm |
2018-07-19 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1624422/000092189518002120/0000921895-18-002120-index.htm |
2018-11-08 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1624422/000092189518002968/0000921895-18-002968-index.htm |
2020-10-13 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1624422/000092189520002591/0000921895-20-002591-index.htm |
2018-05-02 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/1624422/000101915518000110/0001019155-18-000110-index.htm |
2018-07-02 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1624422/000114420418037011/0001144204-18-037011-index.htm |
2018-11-08 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1624422/000114420418058430/0001144204-18-058430-index.htm |
2018-03-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312518079452/0001193125-18-079452-index.htm |
2018-04-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312518114798/0001193125-18-114798-index.htm |
2018-04-24 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1624422/000119312518128812/0001193125-18-128812-index.htm |
2018-05-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312518162754/0001193125-18-162754-index.htm |
2018-05-23 | 20-F/A | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1624422/000119312518172196/0001193125-18-172196-index.htm |
2018-06-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312518182492/0001193125-18-182492-index.htm |
2018-06-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312518186183/0001193125-18-186183-index.htm |
2018-06-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312518193656/0001193125-18-193656-index.htm |
2018-06-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312518201573/0001193125-18-201573-index.htm |
2018-07-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312518219749/0001193125-18-219749-index.htm |
2019-01-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312519001992/0001193125-19-001992-index.htm |
2019-06-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312519168270/0001193125-19-168270-index.htm |
2019-06-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312519180306/0001193125-19-180306-index.htm |
2019-06-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312519182717/0001193125-19-182717-index.htm |
2019-07-16 | F-3 | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1624422/000119312519194786/0001193125-19-194786-index.htm |
2019-07-16 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1624422/000119312519194796/0001193125-19-194796-index.htm |
2019-07-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312519194799/0001193125-19-194799-index.htm |
2019-07-29 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1624422/000119312519204823/0001193125-19-204823-index.htm |
2019-07-30 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1624422/000119312519207053/0001193125-19-207053-index.htm |
2019-09-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312519247553/0001193125-19-247553-index.htm |
2019-09-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312519255964/0001193125-19-255964-index.htm |
2019-11-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312519287886/0001193125-19-287886-index.htm |
2020-02-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520026789/0001193125-20-026789-index.htm |
2020-03-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520076026/0001193125-20-076026-index.htm |
2020-04-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520112721/0001193125-20-112721-index.htm |
2020-04-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520127707/0001193125-20-127707-index.htm |
2020-05-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520137551/0001193125-20-137551-index.htm |
2020-05-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520151592/0001193125-20-151592-index.htm |
2020-06-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520158627/0001193125-20-158627-index.htm |
2020-06-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520164659/0001193125-20-164659-index.htm |
2020-06-25 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1624422/000119312520178939/0001193125-20-178939-index.htm |
2020-06-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520179102/0001193125-20-179102-index.htm |
2020-06-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520181121/0001193125-20-181121-index.htm |
2020-09-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520245772/0001193125-20-245772-index.htm |
2020-09-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520249553/0001193125-20-249553-index.htm |
2020-09-21 | F-3 | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1624422/000119312520250299/0001193125-20-250299-index.htm |
2020-09-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520250342/0001193125-20-250342-index.htm |
2020-10-07 | F-3/A | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1624422/000119312520265551/0001193125-20-265551-index.htm |
2020-10-08 | F-3/A | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1624422/000119312520266426/0001193125-20-266426-index.htm |
2020-10-09 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520267325/0001193125-20-267325-index.htm |
2020-11-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520284804/0001193125-20-284804-index.htm |
2020-11-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1624422/000119312520287535/0001193125-20-287535-index.htm |
2019-03-29 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1624422/000156459019010079/0001564590-19-010079-index.htm |
2020-03-18 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1624422/000156459020011602/0001564590-20-011602-index.htm |
2019-07-30 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1624422/999999999519001732/9999999995-19-001732-index.htm |
2020-10-09 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1624422/999999999520002806/9999999995-20-002806-index.htm |